C

Colinz Laboratories Ltd
BSE:531210

Watchlist Manager
Colinz Laboratories Ltd
BSE:531210
Watchlist
Price: 79.92 INR 20%
Market Cap: ₹201.4m

Relative Value

531210 doesn't have a meaningful market cap.

The Relative Value of one COLINZ stock under the Base Case scenario is hidden INR. Compared to the current market price of 79.92 INR, Colinz Laboratories Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

COLINZ Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Multiples Across Competitors

COLINZ Competitors Multiples
Colinz Laboratories Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Colinz Laboratories Ltd
BSE:531210
201.3m INR 3.4 43.4 30 48.6
US
Eli Lilly and Co
NYSE:LLY
972.2B USD 16.3 52.8 35.4 38
US
Johnson & Johnson
NYSE:JNJ
547.5B USD 5.8 20.4 14.3 17.5
CH
Roche Holding AG
SIX:ROG
277.1B CHF 4.5 29.3 12.4 14.5
UK
AstraZeneca PLC
LSE:AZN
209.4B GBP 4.9 30.1 19.6 28.7
CH
Novartis AG
SIX:NOVN
219B CHF 5 19.3 15.5 20
US
Merck & Co Inc
NYSE:MRK
272.1B USD 4.2 14.3 10.1 12
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK 5.2 15.9 11 12.8
IE
Endo International PLC
LSE:0Y5F
218B USD 94 -74.6 344.9 865
US
Pfizer Inc
NYSE:PFE
148.3B USD 2.4 15.1 7.6 10.4
FR
Sanofi SA
PAR:SAN
93.8B EUR 1.4 6.8 6.2 6.2
P/E Multiple
Earnings Growth PEG
IN
C
Colinz Laboratories Ltd
BSE:531210
Average P/E: 24.7
43.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
52.8
54%
1
US
Johnson & Johnson
NYSE:JNJ
20.4
6%
3.4
CH
Roche Holding AG
SIX:ROG
29.3
29%
1
UK
AstraZeneca PLC
LSE:AZN
30.1
38%
0.8
CH
Novartis AG
SIX:NOVN
19.3
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.3
14%
1
DK
Novo Nordisk A/S
CSE:NOVO B
15.9
2%
7.9
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -74.6 N/A N/A
US
Pfizer Inc
NYSE:PFE
15.1
27%
0.6
FR
Sanofi SA
PAR:SAN
6.8
25%
0.3
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
C
Colinz Laboratories Ltd
BSE:531210
Average EV/EBITDA: 46.1
30
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
35.4
34%
1
US
Johnson & Johnson
NYSE:JNJ
14.3
2%
7.1
CH
Roche Holding AG
SIX:ROG
12.4
5%
2.5
UK
AstraZeneca PLC
LSE:AZN
19.6
10%
2
CH
Novartis AG
SIX:NOVN
15.5
6%
2.6
US
Merck & Co Inc
NYSE:MRK
10.1
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
11
1%
11
IE
E
Endo International PLC
LSE:0Y5F
344.9
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
0%
N/A
FR
Sanofi SA
PAR:SAN
6.2
8%
0.8
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
C
Colinz Laboratories Ltd
BSE:531210
Average EV/EBIT: 97.6
48.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
38
37%
1
US
Johnson & Johnson
NYSE:JNJ
17.5
6%
2.9
CH
Roche Holding AG
SIX:ROG
14.5
6%
2.4
UK
AstraZeneca PLC
LSE:AZN
28.7
23%
1.2
CH
Novartis AG
SIX:NOVN
20
12%
1.7
US
Merck & Co Inc
NYSE:MRK
12
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.8
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
865
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.4
7%
1.5
FR
Sanofi SA
PAR:SAN
6.2
15%
0.4